A prevalent condition affecting millions of American women dramatically increases their chances of developing heart disease, according to a major new nationwide study.
Researchers found that women with polyendocrine metabolic ovarian syndrome, formerly known as polycystic ovary syndrome, face more than four times the risk of serious cardiovascular events compared to those without the condition.
The findings, published Tuesday in The Lancet Obstetrics, Gynaecology & Women’s Health, come from one of the largest analyses of its kind. Experts say the results underscore the need for earlier screening and greater awareness among both patients and doctors.
Heart disease remains the leading cause of death for women in the United States. Public health officials note that traditional risk factors like high blood pressure, high cholesterol, smoking, diabetes and obesity play major roles. Yet this study highlights how the hormonal disorder adds substantial independent danger.
Doctors Snigdha Alur-Gupta and Anuja Dokras, who led the research, said previous evidence had been unclear on whether the condition’s associated risks translated directly into more heart attacks and strokes. Their work now provides stronger confirmation.
The analysis reviewed health insurance records for more than 413,000 women ages 18 to 50 diagnosed with the syndrome between 2000 and 2022. Those patients were compared with more than 2 million women who did not have the condition.
Even after adjusting for obesity, diabetes and other known cardiovascular risks, women with the syndrome still showed a hazard ratio of 4.4 for atherosclerotic cardiovascular disease events. That means they were 4.4 times more likely to experience such problems over the study period.
The syndrome occurs when the ovaries produce excess hormones, leading to symptoms that include irregular menstrual cycles, excessive hair growth, acne and challenges with fertility. Medical sources estimate it affects up to 15 percent of women during their reproductive years.
Experts have long recognized that women with the condition often deal with higher rates of metabolic issues. But the new evidence suggests biological factors tied directly to the syndrome may drive additional heart risks beyond those.
Dr. Roy Jogiya, a cardiologist and chief medical advisor to Heart Research UK, said the study strengthens calls for proactive cardiovascular checks in this group. Early assessment and prevention strategies could make a significant difference, he noted.
The researchers emphasized that the elevated danger persists even in patients who do not have traditional risk factors like hypertension or excess weight. They recommend discussing heart health with patients as part of routine care for the syndrome.
Health advocates point out that better education could help women recognize symptoms sooner and seek appropriate follow-up. Improved long-term monitoring might prevent many future cardiac events.
This research arrives as broader efforts continue to address heart disease disparities in women. Officials stress that cardiovascular issues can strike at any age, with certain conditions amplifying vulnerability.
Clinicians involved in the study called for more provider training to ensure women with the hormonal disorder receive counseling on their heart risks. They also urged ongoing surveillance to catch problems early.
While the findings focus on U.S. data, experts believe the patterns likely apply more widely. Further research could explore specific mechanisms and tailored interventions to lower risks for affected women.
The study authors said their work highlights an important opportunity to improve outcomes through awareness and preventive steps rather than waiting for complications to develop.
